Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors

Despite efforts to understand and treat acute myeloid leukemia (AML), there remains a need for more comprehensive therapies to prevent AML-associated relapses. To identify new therapeutic strategies for AML, we screened a library of on- and off-patent drugs and identified the antimalarial agent mefl...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Sukhai, Mahadeo A., Prabha, Swayam, Hurren, Rose, Rutledge, Angela C., Lee, Anna Y., Sriskanthadevan, Shrivani, Sun, Hong, Wang, Xiaoming, Skrtic, Marko, Seneviratne, Ayesh, Cusimano, Maria, Jhas, Bozhena, Gronda, Marcela, MacLean, Neil, Cho, Eunice E., Spagnuolo, Paul A., Sharmeen, Sumaiya, Gebbia, Marinella, Urbanus, Malene, Eppert, Kolja, Dissanayake, Dilan, Jonet, Alexia, Dassonville-Klimpt, Alexandra, Li, Xiaoming, Datti, Alessandro, Ohashi, Pamela S., Wrana, Jeff, Rogers, Ian, Sonnet, Pascal, Ellis, William Y., Corey, Seth J., Eaves, Connie, Minden, Mark D., Wang, Jean C.Y., Dick, John E., Nislow, Corey, Giaever, Guri, Schimmer, Aaron D.
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Clinical Investigation 2012
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3533286/
https://ncbi.nlm.nih.gov/pubmed/23202731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI64180
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares